MIRA Pharmaceuticals’ Ketamir-2 Published in Pharmacology Journal

MIRA Pharmaceuticals, Inc. ( (MIRA) ) has provided an announcement.

On June 17, MIRA Pharmaceuticals announced that its lead drug candidate, Ketamir-2, has been accepted for publication in the journal Frontiers in Pharmacology, highlighting its potential as a differentiated oral alternative to traditional ketamine. The publication validates Ketamir-2’s unique pharmacological profile, including selective NMDA antagonism and improved bioavailability, with ongoing Phase 1 trials progressing without safety concerns. The company plans to initiate a Phase 2a trial by the end of 2025 and is advancing the acquisition of SKNY Pharmaceuticals, which includes a novel treatment for obesity and smoking cessation.

The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.

More about MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing innovative drug candidates. The company is engaged in clinical trials for its lead drug candidate, Ketamir-2, targeting neuropathic pain, and is also involved in the acquisition of SKNY Pharmaceuticals, which develops treatments for obesity and smoking cessation.

Average Trading Volume: 1,232,322

Technical Sentiment Signal: Hold

Learn more about MIRA stock on TipRanks’ Stock Analysis page.